Can a new pill shorten COVID-19 symptoms?

NCT ID NCT07746544

Not yet recruiting Disease control Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether the oral drug secutrelvir can help people with COVID-19 recover faster. The study involves about 1,200 nonhospitalized participants aged 12 to 75 who start treatment within 48 hours of symptom onset. Half will receive secutrelvir and half a placebo, and researchers will track how quickly 14 common COVID-19 symptoms resolve. The goal is to see if secutrelvir can shorten the illness and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secutrelvir (also known as S-892216), an oral antiviral drug taken as a tablet
What this could lead to: If successful, secutrelvir could become a new treatment option to help people with COVID-19 feel better faster and reduce the burden of the disease.
What could go wrong: This is a phase 3 trial, but results are not guaranteed. The drug may not significantly speed up symptom resolution, and there could be side effects not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Japanese Site 1

Multiple Locations, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.